| S2 Resources Limited (S2R) ORDINARY FULLY PAID |
Materials |
$35 |
45% owned Valkea hits significant gold in drilling - Finland
|
28 Feb 2025 8:48AM |
$0.062 |
$0.066 |
risen by
6.45%
|
|
S2R - Price-sensitive ASX Announcement
Full Release
Key Points
- 45%-owned TSXV-listed Valkea Resources has intersected significant gold mineralisation.
- Drilling has defined two distinct zones, named Koivu and Honka.
- Key intercepts include 36.45 metres @ 1.5g/t gold, including 15.35 metres @ 3.43g/t gold.
- Both zones are open down dip; Koivu zone is also open along strike.
- Aarnivalkea gold prospect is located 24 kilometres northwest of Agnico Eagle’s Kittila gold mine.
- S2 Resources sold its Finnish subsidiary owning Aarnivalkea deposit to Valkea in September 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| SomnoMed Limited (SOM) ORDINARY FULLY PAID |
Health Care |
$150 |
FY25 Half Year Results
|
28 Feb 2025 8:47AM |
$0.600 |
$0.685 |
risen by
14.17%
|
|
SOM - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 H1 revenue increased to $53.7 million, up 19.0% from FY24 H1.
- Gross margin remains consistent at 62%.
- EBITDA of $5.8 million versus a loss of $1.1 million in the previous period.
- Cash balance improved to $18.5 million at December 31, 2024.
- Total patients treated worldwide are approximately 960,000.
- Manufacturing capacity increased by over 40% compared to the prior period.
- Production backlog reduced from over 2 weeks to under 2 days.
- Guidance for FY25 includes revenue of approximately $105 million and EBITDA of $7-9 million.
- Positive trends in growth expected to continue, though potential slowing in the latter half of FY25.
- FDA cleared Rest Assure® as the first oral device with in-built compliance monitoring.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Maximus Resources Limited (MXR) ORDINARY FULLY PAID |
Materials |
- |
Change in substantial holding from AAR
|
28 Feb 2025 8:47AM |
$0.062 |
$0.077 |
risen by
24.19%
|
|
| Astral Resources NL (AAR) ORDINARY FULLY PAID |
Materials |
$509 |
Change in substantial holding for MXR
|
28 Feb 2025 8:47AM |
$0.135 |
$0.283 |
risen by
109.26%
|
|
| Future Generation Australia Limited (FGX) ORDINARY FULLY PAID |
Financials |
$559 |
Appendix 4G
|
28 Feb 2025 8:47AM |
$1.270 |
$1.360 |
risen by
7.09%
|
|
| Bioxyne Limited (BXN) ORDINARY FULLY PAID |
Consumer Staple |
$96 |
Half Yearly Report and Accounts
|
28 Feb 2025 8:46AM |
$0.034 |
$0.043 |
risen by
26.47%
|
|
BXN - Price-sensitive ASX Announcement
Full Release
Key Points
- Record sales revenue of $12,563,277 for H1 FY25.
- 171% increase in sales compared to H1 FY24.
- Awarded a GMP manufacturing license for medicinal cannabis products.
- First in Australia to manufacture Psilocybin and MDMA products outside of clinical trials.
- Expansion of manufacturing operations and product offerings in Australia and overseas.
- Invested approximately $1.3 million to increase manufacturing capacity.
- Positive operating cash inflow of $2,957,363.
- Expected revenue guidance of $25 million for FY30 June 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Weebit Nano Ltd (WBT) ORDINARY FULLY PAID |
Information Technology |
$1,035 |
Half Year Results Announcement
|
28 Feb 2025 8:46AM |
$2.210 |
$4.920 |
risen by
122.62%
|
|
WBT - Price-sensitive ASX Announcement
Full Release
Key Points
- Weebit Nano signed a licensing agreement with onsemi for ReRAM technology integration.
- The company has a strong cash balance of A$97 million as of 31 December 2024.
- A capital raise of A$50 million was completed at a 6.5% premium.
- Expanded IP portfolio with 13 new patents, totaling over 80 patents related to ReRAM.
- Technology transfer to DB HiTek is advancing with demo chips under testing.
- Promotion of Lilach Zinger to VP Customer Success to enhance customer relations.
- Ambitious targets set for multiple new agreements with fabs and product companies by end of 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| archTIS Limited (AR9) ORDINARY FULLY PAID |
Information Technology |
$42 |
Half Year Accounts
|
28 Feb 2025 8:46AM |
$0.078 |
$0.088 |
risen by
12.82%
|
|
AR9 - Price-sensitive ASX Announcement
Full Release
Key Points
- ARR of $4.0M, up 11% on previous year.
- Total revenue of $2.77M, including $1.95M from licensing.
- Gross margin increased to 74%.
- Comprehensive loss of $2.47M for the half-year.
- Secured $2.3M contract with Australian Department of Defence.
- Launched new product for structured data integration and security.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Weebit Nano Ltd (WBT) ORDINARY FULLY PAID |
Information Technology |
$1,035 |
Appendix 4D & FY25 Interim Financial Statements
|
28 Feb 2025 8:45AM |
$2.210 |
$4.920 |
risen by
122.62%
|
|
WBT - Price-sensitive ASX Announcement
Full Release
Key Points
- Weebit Nano Limited reported a loss of A$22.7 million for HY25.
- The company achieved a 341% increase in revenue from ordinary activities.
- A licensing agreement with onsemi was signed for ReRAM technology integration.
- The group raised A$50 million in new capital to support growth.
- The net working capital surplus was reported at A$95.1 million.
- There were no dividends declared during the reporting period.
- The company aims to secure new agreements with foundries and product companies in 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vmoto Limited (VMT) ORDINARY FULLY PAID |
Consumer Discretionary |
$30 |
Preliminary Final Report
|
28 Feb 2025 8:45AM |
$0.088 |
$0.076 |
fallen by
13.64%
|
|
VMT - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue of $58.7 million for FY24, down 15% from FY23.
- Net profit after tax of $149,000, down 98% compared to FY23.
- Total sales of 17,038 units of e-motorcycles and e-mopeds, down 32% on FY23.
- Initiatives to mitigate sales impact include support to distributors and pursuing new sales opportunities.
- Vmoto unified its brands under one iconic 'Vmoto' brand.
- Invested in Zenion Limited, a UK operator for last mile delivery services.
- Joint ventures established in South Africa, Thailand, and Mexico.
- Commenced setting up manufacturing facilities in Thailand.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Renu Energy Limited (RNE) ORDINARY FULLY PAID |
Utilities |
$0 |
Proposed issue of securities - RNE
|
28 Feb 2025 8:44AM |
$0.001 |
$0.001 |
fallen by
0%
|
|
| Metals X Limited (MLX) ORDINARY FULLY PAID |
Materials |
$1,126 |
Appendix 4E and Annual Financial Report
|
28 Feb 2025 8:44AM |
$0.550 |
$1.270 |
risen by
130.91%
|
|
MLX - Price-sensitive ASX Announcement
Full Release
Key Points
- Total comprehensive income after tax of $101.85 million.
- Revenue increased by 42% to $218.82 million.
- Record annual tin production of 11,006 tonnes.
- Share buy-back program successfully executed.
- Investment in First Tin PLC acquired 29.91% interest.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| VGI Partners Global Investments Limited (VG1) ORDINARY FULLY PAID |
Financials |
- |
Update - Notification of buy-back - VG1
|
28 Feb 2025 8:44AM |
$1.880 |
$1.950 |
risen by
3.72%
|
|
| Metro Mining Limited (MMI) ORDINARY FULLY PAID |
Materials |
$409 |
2024 Annual Results Announcement
|
28 Feb 2025 8:43AM |
$0.054 |
$0.067 |
risen by
24.07%
|
|
MMI - Price-sensitive ASX Announcement
Full Release
Key Points
- 24% increase in shipped production to 5.7 million WMT
- 30% increase in revenue to $307 million
- 100% increase in Underlying EBITDA to $37 million
- 35% reduction in net debt
- Production and shipment guidance for 2025 set at 6.5 to 7.0 million WMT
- The $36 million expansion is complete with full flow sheet in place
- Bauxite Hills Mine demonstrated capacity to operate at target rate of 7 million WMT per annum
- Metro expects further economies of scale in 2025
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lake Resources NL (LKE) ORDINARY FULLY PAID |
Materials |
$205 |
Notification of cessation of securities - LKE
|
28 Feb 2025 8:43AM |
$0.037 |
$0.089 |
risen by
139.19%
|
|
| Greenhy2 Limited (H2G) ORDINARY FULLY PAID |
Industrials |
$6 |
Preliminary Final Report and Appendix 4E
|
28 Feb 2025 8:42AM |
$0.003 |
$0.009 |
risen by
200%
|
|
H2G - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss after tax was $1,156,627, a 33% improvement from the previous year.
- Cash on hand increased to $1,041,385, up 4% from last year.
- Focus on Renewable Energy Strategy with Hydrogen Storage Batteries.
- Cost reduction strategy resulted in supplier savings of 30% to 50%.
- Significant progress on the Telstra project, under budget and on schedule.
- GreenHy2 is actively tendering for new projects and exploring emerging technologies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Next Science Limited (NXS) ORDINARY FULLY PAID |
Health Care |
$42 |
FY24 Annual Result Investor Presentation
|
28 Feb 2025 8:42AM |
$0.105 |
$0.145 |
risen by
38.10%
|
|
NXS - Price-sensitive ASX Announcement
Full Release
Key Points
- Net Operating Cash Outflow of US$8.0m in FY24 compared to US$15.1m in FY23.
- Closing cash balance of US$1.7m at 31 December 2024 and debt of US$2.0m.
- Revenue of US$22.8m, up 3% on prior corresponding period.
- Significant growth in sales of XPERIENCE® due to increased clinical evidence.
- Received FDA Warning Letter on 25 Feb 2025 but confirmed product safety.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Renu Energy Limited (RNE) ORDINARY FULLY PAID |
Utilities |
$0 |
Proposed issue of securities - RNE
|
28 Feb 2025 8:41AM |
$0.001 |
$0.001 |
fallen by
0%
|
|
| WEB Travel Group Limited (WEB) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,333 |
Update - Notification of buy-back - WEB
|
28 Feb 2025 8:41AM |
$4.920 |
$3.690 |
fallen by
25%
|
|
| Next Science Limited (NXS) ORDINARY FULLY PAID |
Health Care |
$42 |
Next Science reports FY24 Result
|
28 Feb 2025 8:41AM |
$0.105 |
$0.145 |
risen by
38.10%
|
|
NXS - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue of US$22.8m, up 3% on pcp
- Total sales of XPERIENCETM up 85%
- Direct product sales of US$17.4m, up 3% on pcp
- Gross profit of US$18.4m, up 14% on pcp
- Gross margin improved to 81%
- Operating expenses decreased by 15%
- Adjusted EBITDA loss of -US$8.0m, improved by 46%
- Cash receipts of US$22.7m, up 13% vs pcp
- FDA Warning Letter received regarding Jacksonville facility
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| SomnoMed Limited (SOM) ORDINARY FULLY PAID |
Health Care |
$150 |
Half Yearly Report and Accounts
|
28 Feb 2025 8:41AM |
$0.600 |
$0.685 |
risen by
14.17%
|
|
SOM - Price-sensitive ASX Announcement
Full Release
Key Points
- SomnoMed Limited's financial performance reflects significant growth.
- The report outlines strategic initiatives for market expansion.
- Cost management has been a key focus to enhance profitability.
- Investments are directed towards improving product offerings.
- The company is committed to delivering shareholder value.
- Future growth is anticipated amidst evolving market conditions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Metro Mining Limited (MMI) ORDINARY FULLY PAID |
Materials |
$409 |
Appendix 4G and Corporate Governance Statement
|
28 Feb 2025 8:40AM |
$0.054 |
$0.067 |
risen by
24.07%
|
|
| Thorney Technologies Ltd (TEK) ORDINARY FULLY PAID |
Financials |
$49 |
Update - Notification of buy-back - TEK
|
28 Feb 2025 8:40AM |
$0.135 |
$0.130 |
fallen by
3.70%
|
|
| LTR Pharma Ltd (LTP) ORDINARY FULLY PAID |
Health Care |
$96 |
LTR Pharma to Showcase SPONTAN Data at Urology Conference
|
28 Feb 2025 8:40AM |
$0.625 |
$0.530 |
fallen by
15.20%
|
|
LTP - Price-sensitive ASX Announcement
Full Release
Key Points
- LTR Pharma to Present SPONTAN Clinical Data at Major Urological Conference
- SPONTAN achieves 470% faster absorption than current ED tablets
- Presentation validates SPONTAN's potential to disrupt the global ED market
- Conference strengthens SPONTAN's profile with key prescribers
- Professor Eric Chung to share breakthrough clinical results demonstrating significant advantages over existing treatments
- SPONTAN shows a mean time to maximum plasma concentration of 12 minutes
- Results achieved with half the drug dose of oral tablets while maintaining bioavailability
- Real-world patient feedback under TGA's Special Access Scheme supports findings
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Shine Justice Ltd (SHJ) ORDINARY FULLY PAID |
Consumer Discretionary |
$124 |
FY25 Half Year Results Presentation
|
28 Feb 2025 8:36AM |
$0.720 |
$0.730 |
risen by
1.39%
|
|
SHJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Statutory revenue increased to $100.7 million from $98.3 million.
- Net income from the Personal Injury segment was $82 million.
- Class Action segment faced a slight revenue downturn due to delays in new filings.
- Robust pipeline of opportunities in Class Actions is expected to improve profitability.
- A fully franked interim dividend of 1.5 cents per share was declared.
- Strategic focus on operational efficiency and market expansion.
- Carolyn Barker appointed as CEO effective 28 February 2025.
- Positive outlook for the second half of FY25.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
